SiliconInvestor
     Advanced Search   [ sign in ]

register
Sponsor		  register
Register

Profile for scaram(o)uche
Add PeopleMarkIgnore MemberSend Private MessageRecent Posts

Site Participation
Date Joined Jun 9 1996 User Level
Posts 27274 Boards Moderated47
PeopleMarks 335 Bans Issued 0
Ignored By 9 Bans Received 1

Personal Information
Age: old
College: UCLA School of Medicine
Degree: Ph.D., Immunogenetics
Investment Style: Depends on the nature of the market. At times, search for multi-baggers. Lately, position trades and patience. 'Remember to keep one foot in the gutter while fishing for gold'.
Investment Experience: way too much
Interests and Hobbies: bitching
Quote: I'm not bad, I'm just drawn that way.
25 Most Recent SubjectsLast PostPosts
Oncothyreon05-21-13 07:58 PM 124
momo-T/FIF05-21-13 04:46 PM 3,506
Indications -- Cancer05-19-13 04:36 PM 134
Biotechnology Value Fund, L.P.05-17-13 11:25 PM 2,182
Incyte Pharmaceuticals (INCY)05-16-13 01:07 PM 232
biotech firesales05-16-13 11:12 AM 190
ARIAD Pharmaceuticals05-15-13 11:08 PM 191
The Securities and Exchange Commission 05-06-13 10:24 AM 232
Biotech Valuation05-05-13 06:31 PM 1,497
Regeneron Pharmaceuticals05-01-13 03:18 PM 119
biotech fireworks05-01-13 11:13 AM 357
E.Schwab problems04-23-13 03:55 PM 346
Array Pharmaceuticals ARRY 04-22-13 12:55 PM 117
Catalyst Pharmaceutical Partners04-22-13 12:31 PM 2
Vertex Pharmaceuticals (VRTX)04-18-13 04:29 PM 87
Indications -- Sepsis/Acute Inflammation04-17-13 09:54 AM 27
Indications -- Depression04-13-13 02:19 PM 9
Indications -- obesity/erectile dysfunction04-13-13 02:17 PM 175
Indications - Neurodegenerative04-08-13 10:40 AM 56
Exelixis, Inc. (EXEL)03-17-13 03:34 PM 96
NAKED SHORTING-Hedge Fund & Market Maker manipulation?03-08-13 03:45 PM 41
CNBC -- critique.03-04-13 08:23 PM 128
Infinity Pharmaceuticals 03-04-13 05:20 PM 5
Indications -- scarring, fibrosis, adhesions, keloids03-01-13 01:21 PM 11
Indications -- pain02-28-13 12:59 PM 42
Read Last    Messages  
List Last    Messages  

Posts by scaram(o)uche
MessageSubjectRecsDate/Time (ET)
parking, hope it works..... [url=http://abstractsearch.asco.org/cgi-bin/ts.plOncothyreon 05/21/2013 07:58:12 PM
everything is clear, now...... [url=http://www.sciencenews.org/view/feature/imomo-T/FIF 05/21/2013 04:46:43 PM
So, plenty. This from today, a nice "up to date"......... [url=http://www.momo-T/FIF 05/21/2013 03:48:27 PM
Steve, it's going to be tough to get a standing-room-only space at Butts' presenOncothyreon 05/21/2013 01:47:37 PM
So this would be what the average Joe/Jane would look like.... Concurrent: Oncothyreon 05/20/2013 02:38:01 PM
>> concurrent CRT demonstrated significant benefit in terms of response rate, ovOncothyreon 05/20/2013 02:03:23 PM
>> if it sees IgE on the surface of B cells differentiated to produce E << Thmomo-T/FIF 05/20/2013 12:28:41 PM
Sounds like xolair with more punch? You'd want to know if it sees IgE on the momo-T/FIF 05/20/2013 10:45:58 AM
There are statisticians who are saying that this cut in the data is like blue eyOncothyreon 05/19/2013 06:22:45 PM
Reviewing my recent flip-flop, on data that has accumulated in recent years.... momo-T/FIF 05/19/2013 05:27:03 PM
Only interested in the tumorigenesis bit, don't buy last sentence (would love toIndications -- Cancer 05/19/2013 04:36:12 PM
Did my first postdoc at Max Planck Immunogenetics, Tuebingen. But I had another momo-T/FIF 05/19/2013 01:22:06 PM
>> Rationale for abiraterone trial given in prostate abstract. Cool. Part B of tOncothyreon 05/18/2013 04:10:53 PM
urrrrrrgggggghhhhhh..... that one stayed up through the edit period. ThoughOncothyreon 05/17/2013 11:30:15 PM
Relatively large block dropped today between the bid-ask and I don't think it waBiotechnology Value Fund, L.P. 05/17/2013 11:25:48 PM
Acute haematological toxicity grade 3/4 was more pronounced in the sequential (SOncothyreon 05/17/2013 11:09:56 PM
Not a pukin' chance that proximity of C to irradiation was a factor. Sorry. Oncothyreon 05/17/2013 08:10:29 PM
OK, this time I am leaving. Walking out. Gonna be a long drive now, was planningmomo-T/FIF 05/17/2013 09:52:17 AM
As you know, clinical trials are experiments..... they're experiments using humaOncothyreon 05/17/2013 09:21:01 AM
Cool, thanks for the perspective. To me, it was a "gang up and distribute misinOncothyreon 05/17/2013 09:18:14 AM
Don't think he saw it...... ;-)Biotechnology Value Fund, L.P. 05/16/2013 11:43:23 PM
Stayed away from Twitter today, to avoid having my nose rubbed in it. But took aOncothyreon 05/16/2013 11:29:24 PM
>> and a new adjuvant, a tlr4 agonist << That is, an old adjuvant in a new cIncyte Pharmaceuticals (INCY) 05/16/2013 01:07:45 PM
Run, Orb, run! (thanks) Outta here for a long weekend. edit: I retirmomo-T/FIF 05/16/2013 12:43:49 PM
>> The mucin 1 vaccine that Biomira launched seems to work << The vaccine coIncyte Pharmaceuticals (INCY) 05/16/2013 12:38:36 PM
Thanks! Voiced this opinion, in a different thread.... I want to be clear aOncothyreon 05/16/2013 12:27:14 PM
Reminder for next year, in event that the wet-behind-ears guys are still fear momomo-T/FIF 05/16/2013 12:18:59 PM
Mark Lampert: I met you many years ago, a tour of your then-small operation aBiotechnology Value Fund, L.P. 05/16/2013 11:41:37 AM
Hey, thanks! Some of that will be useful. Sales recommended the Alexander Technimomo-T/FIF 05/16/2013 11:17:32 AM
another comment..... my basis is under $2, and way, way under if you count all tbiotech firesales 05/16/2013 11:12:27 AM
And there's nothing I like as much as whiplash. Been a couple of years since I sbiotech firesales 05/16/2013 10:59:15 AM
Merck can get this vaccine approved with a blindfold, if there are long-term surbiotech firesales 05/16/2013 10:41:48 AM
21% and falling. ONTYbiotech firesales 05/16/2013 10:22:06 AM
2.06 filling now........Oncothyreon 05/16/2013 10:19:31 AM
set up lowball bids this morning, at 2.06 and 2.16. 2.16 just got a partial hit.Oncothyreon 05/16/2013 10:08:52 AM
onty.... post-asco abstract release selling, 15%. Please see the thread if inbiotech firesales 05/16/2013 10:06:25 AM
schade..... http://finance.yahoo.com/echarts?s=MRK.DE+Interactive#symbol=mrkOncothyreon 05/15/2013 11:49:16 PM
Went to a talk by Polly Matzinger at Cal, maybe 8-10 years ago. Probably with MaOncothyreon 05/15/2013 11:41:43 PM
>> tolerability looks much better than LDK << Thanks.ARIAD Pharmaceuticals 05/15/2013 11:08:55 PM
Certain that you know, but the "asian population" trial will enroll 420. HaveOncothyreon105/15/2013 10:48:00 PM
A FIRST FOR BIOTECH..... subset analysis that yields positive results but doesOncothyreon 05/15/2013 10:30:08 PM
Sure can tell the guys at twitter who have mixed interests, portfolio at work veOncothyreon 05/15/2013 10:19:10 PM
>> No major practical issues were identified during setup and early conduct of tOncothyreon 05/15/2013 09:46:11 PM
>> If you're a lottery freak? Good luck, been fun thus far! << My, my. BeingOncothyreon 05/15/2013 09:18:32 PM
I just reread your message and realized that a response that I've been drafting Incyte Pharmaceuticals (INCY) 05/15/2013 08:51:20 PM
Jim....... Something big happened. The mucin 1 vaccine that Biomira launchedIncyte Pharmaceuticals (INCY) 05/15/2013 08:27:31 PM
Nothing particularly encouraging in either px-866 abstract, and can't imagine whOncothyreon 05/15/2013 07:11:14 PM
30.8 versus 20.6 months, n=806....... http://abstracts2.asco.org/resources/pOncothyreon 05/15/2013 06:40:45 PM
And, btw, chemo and radiation are immunosuppressive. Results make sense. All I hOncothyreon 05/15/2013 06:30:22 PM
Is there some secret to getting into the *&^&%$ abstracts??? Thanks to AF...Oncothyreon 05/15/2013 06:19:36 PM

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQ
Copyright © 1995-2013 Knight Sac Media. All rights reserved.